Institut De Recherche Pour Le Developpement (ird)

Centre National De La Recherche Scientifique

Universitè De Montpellier

Université´ D'aix-marseille

Université Cote D'azur

Ecole Nationale Superieure De Chimie

Francisco Veas

Céline Crauste

Thierry Durand

Joseph Vercauteren

Martine Cerutti

Nicolas Blondeau

The present invention relates to compound of formula (I): whereinR is O&#x2014;Ror Rand Rare identical or different and are each independently H, (C-C)alkyl, &#x2014;CO&#x2014;(C-C)alkyl or &#x2014;CO&#x2014;(C-C)alkenyl group, provided that at least one of Ror Ris H or (C-C)alkyl,Ris a &#x2014;CO&#x2014;(C-C)alkyl or &#x2014;CO&#x2014;(C-C)alkenyl group,or its pharmaceutically acceptable salts, racemates, diastereoisomers, enantiomers, or mixtures thereof,for use in prevention and/or treatment of a disease or disorder linked to an exacerbated vascular, lymphatic or mucosal permeability.

Uses of lipophenolic compounds

An isolated and purified human immunodeficiency virus type 1 (HIV-1) mutant gp120 envelope glycoprotein containing an amino acid mutation in positionwhich contains replacement of W with S, I, or F, wherein the numbering scheme is based upon the molecular clone HxBc2.

Gp120 mutants and biological applications

Growing community of inventors

Mauguio, France

Francisco Veas